Literature DB >> 17664384

Beyond unfractionated heparin and warfarin: current and future advances.

Jack Hirsh1, Martin O'Donnell, John W Eikelboom.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17664384     DOI: 10.1161/CIRCULATIONAHA.106.685974

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  33 in total

1.  [Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine].

Authors:  D C Gulba; L Broscaru
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-01-31       Impact factor: 0.840

2.  Bleeding hearts.

Authors:  Nigel Mackman
Journal:  Blood       Date:  2009-01-15       Impact factor: 22.113

Review 3.  Novel treatments for cardiovascular disease prevention.

Authors:  Mark D Huffman; Deepak Bhatnagar
Journal:  Cardiovasc Ther       Date:  2011-05-31       Impact factor: 3.023

4.  The anticoagulant effect of heparin during radiofrequency ablation (RFA) in patients taking apixaban or rivaroxaban.

Authors:  L C Brendel; F Dobler; G Hessling; J Michel; S L Braun; A L Steinsiek; P Groha; R Eckl; I Deisenhofer; A Hyseni; M Roest; I Ott; B Steppich
Journal:  J Interv Card Electrophysiol       Date:  2017-07-22       Impact factor: 1.900

5.  Homogeneous low-molecular-weight heparins with reversible anticoagulant activity.

Authors:  Yongmei Xu; Chao Cai; Kasemsiri Chandarajoti; Po-Hung Hsieh; Lingyun Li; Truong Q Pham; Erica M Sparkenbaugh; Juzheng Sheng; Nigel S Key; Rafal Pawlinski; Edward N Harris; Robert J Linhardt; Jian Liu
Journal:  Nat Chem Biol       Date:  2014-02-23       Impact factor: 15.040

6.  Venous thromboembolism in the elderly. A community-based perspective.

Authors:  Frederick A Spencer; Joel M Gore; Darleen Lessard; Cathy Emery; Luigi Pacifico; George Reed; Jerry H Gurwitz; Robert J Goldberg
Journal:  Thromb Haemost       Date:  2008-11       Impact factor: 5.249

Review 7.  Triggers, targets and treatments for thrombosis.

Authors:  Nigel Mackman
Journal:  Nature       Date:  2008-02-21       Impact factor: 49.962

Review 8.  New options with dabigatran etexilate in anticoagulant therapy.

Authors:  Lars Maegdefessel; Joshua M Spin; Junya Azuma; Philip S Tsao
Journal:  Vasc Health Risk Manag       Date:  2010-05-25

Review 9.  Secondary prevention strategies for coronary heart disease.

Authors:  Shepard D Weiner; LeRoy E Rabbani
Journal:  J Thromb Thrombolysis       Date:  2010-01       Impact factor: 2.300

Review 10.  The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.

Authors:  Andrew D Blann; Chee W Khoo
Journal:  Vasc Health Risk Manag       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.